Capsid Inhibitors' Next Growth Test: Turning Longer Dosing into Durable Access and Treatment Value

Twice-yearly prevention, simplified HIV treatment combinations and hepatitis B pipeline programs are widening the market opportunity-but clinical differentiation must translate into accessible, durable use.

The global capsid inhibitor market is projected to grow from US$1.42 billion in 2025 to US$7.86 billion by 2035, representing an 18.7% CAGR from 2026 to 2035, according to DataM Intelligence. HIV capsid inhibitors currently generate most market revenue, with long-acting prevention and treatment combinations expanding the class beyond its initial, specialist use. Hepatitis B capsid assembly modulators represent a separate, pipeline-led opportunity.

This market's growth story depends on more than the duration of a drug's effect. Longer intervals between doses could ease daily adherence burdens and support prevention programs, but uptake also depends on price, testing, follow-up and reliable supply. For treatment, the commercial question is whether capsid-based combinations can simplify regimens for additional patient groups while maintaining viral suppression.

Request Executive Sample: https://www.datamintelligence.com/download-sample/capsid-inhibitor-market?kailas

Recent Developments

- August 2026: The U.S. FDA approved Gilead's Bixlenvo, a once-daily single-tablet combination of bictegravir and lenacapavir for eligible adults with suppressed HIV, including some people on complex treatment regimens.

- July 2026: Aligos completed enrollment in its Phase 2 B-SUPREME study of pevifoscorvir sodium in chronic hepatitis B. The approximately 250-participant trial is comparing the investigational capsid assembly modulator with tenofovir; the company anticipates topline results in late 2027.

- June 2026: Gilead and Merck reported positive topline Phase 3 results from ISLEND-1 and ISLEND-2, evaluating a once-weekly oral combination of islatravir and lenacapavir for HIV treatment.

- June 2026: The FDA accepted Gilead's application for a potential once-weekly oral lenacapavir formulation for HIV pre-exposure prophylaxis (PrEP), setting an action date of February 2, 2027.

- April 2026: The FDA granted Fast Track designation to Aligos' pevifoscorvir sodium. The Phase 2 study's independent monitoring board recommended continuing the trial and increasing the size of one participant cohort; the prespecified futility criteria were not met.

- March 2026: Assembly Biosciences said Gilead had declined to exercise its option on ABI-4334, returning full control of the HBV capsid assembly modulator to Assembly. The company began evaluating potential partners and said it did not plan to advance the program without one.

- July 2025: The World Health Organization recommended twice-yearly injectable lenacapavir as an additional HIV prevention option, alongside combination prevention and simplified rapid testing guidance.

Purchase This Exclusive Report: https://www.datamintelligence.com/buy-now-page?report=capsid-inhibitor-market?kailas

Additional Benefits:
✅ Get Interactive Dashboard Access (With No Additional Cost)
✅ Three months of analyst support to answer queries related to the report.

Market Segmentation

HIV capsid inhibitors are the current commercial anchor. Lenacapavir has established the class in treatment and prevention and is now being developed in additional formats and combinations. The approval of Bixlenvo adds a once-daily treatment option for eligible adults, while the once-weekly islatravir-lenacapavir program could broaden dosing choices if it progresses through regulatory review. These distinct regimens create different commercial pathways: treatment combinations compete on regimen suitability and maintained suppression, while prevention products must also demonstrate that administration and follow-up can work at scale. DataM Intelligence identifies HIV capsid inhibitors as the leading inhibitor class and estimates that they generated most market revenue in 2025.

HIV prevention is the fastest-growing indication opportunity, but access will determine its reach. Twice-yearly dosing could offer an alternative for people who find daily PrEP difficult to maintain. The opportunity depends on implementation: programs need reliable HIV testing, scheduled administration, patient follow-up and supply planning. WHO's recommendation supports its inclusion as an additional prevention option, while Gilead's application for a weekly oral formulation signals that the market may serve people with different preferences around injections. Lower-frequency dosing can differentiate a product, but sustained uptake will depend on affordability and delivery capacity as well as clinical performance.

Company Profiles

Gilead Sciences has the leading commercial position through lenacapavir, which features in its treatment and PrEP portfolio. The Bixlenvo approval extends the molecule into a daily oral combination, while the accepted application for weekly oral PrEP and Phase 3 once-weekly treatment results point to further lifecycle expansion. The portfolio spans multiple dosing formats, but each requires its own evidence, regulatory review and implementation strategy.

Merck & Co. is collaborating with Gilead on the once-weekly islatravir-lenacapavir treatment regimen. Positive Phase 3 topline results move the program into a later development stage and show how partnering can combine complementary antiviral mechanisms. Future value will depend on the full clinical and regulatory package and whether weekly dosing provides a meaningful option alongside existing treatments.

Aligos Therapeutics is advancing pevifoscorvir sodium, an oral capsid assembly modulator for chronic hepatitis B. Fast Track designation and Phase 2 enrollment completion mark progress, but topline results are expected in 2027. The program's commercial potential will depend on efficacy and safety results, its role in combination regimens and whether it can contribute to more durable control of HBV.

Assembly Biosciences is developing ABI-4334, a next-generation HBV capsid assembly modulator. With Gilead no longer pursuing its option, Assembly retains control and is seeking a partner to support further development. The situation highlights the importance of financing and licensing strategy in a category where long clinical timelines and combination requirements can make development difficult for smaller biotechs.

The market's next phase will be shaped by whether capsid inhibitors can convert dosing convenience into durable use and measurable health-system value. HIV prevention brings the largest incremental volume opportunity, while simplified treatment regimens could expand the eligible population. HBV programs offer long-term potential but remain dependent on clinical evidence and combination development. Across all three paths, affordability, follow-up systems and reliable supply will be central to turning pipeline progress into lasting commercial growth.

Request a Customized Report According to Your Business Strategy: https://www.datamintelligence.com/customize/capsid-inhibitor-market?kailas

Contact Us:
Sai Kiran
Business Development Manager
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, Lalitha Nagar, Habsiguda,
Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com

About DataM Intelligence
DataM Intelligence provides market research and competitive analysis across global industries. Its Capsid Inhibitor Market report examines market size, clinical pipelines, indications, formats, regions and company positioning.

This release was published on openPR.